sFRP and Peptide Motifs That Interact with sFRP and Methods of Their Use
Description of Invention:
These patent applications describe and claim inventions related to the protein sFRP-1 and methods of regulating signal transduction pathways using sFRP-1. sFRP-1 is a member of a family of secreted proteins (secreted Frizzled Related Proteins) that were originally identified as being able to bind to Wnt proteins. When bound to Wnts, sFRP-1 alters the ability of Wnt protein to bind its receptor (Frizzled), typically acting as an antagonist of Wnt signaling.
More particularly, the patent applications and inventions claimed therein relate to methods for influencing bone remodeling using sFRP-1. In particular, the patent application and claimed inventions relate to methods of inhibiting osteoclastogenesis with the sFRP-1 protein. The ability to inhibit osteoclast formation may be of value in developing treatments for diseases such as post menopausal osteoporosis, Paget's disease, lytic bone metastases, multiple myeloma, hyperparathyroidism, rheumatoid arthritis, periodontitis and hypercalcemia of malignancy.
In addition to describing the method of inhibiting osteoclast formation, the patent applications disclose various peptides containing a conserved motif that allows the peptide containing the motif to bind to sFRP-1.
Inventors:
Jeffrey S. Rubin (NCI) Aykut Uren (NCI) et al.
Patent Status:
DHHS Reference No. E-060-2000/0 --
U.S. Provisional Application No. 60/260,908 filed 10 Jan 2001
DHHS Reference No. E-060-2000/1 --
PCT Application No. PCT/US02/00869 filed 10 Jan 2002, which published as WO 02/055547 on 10 Jul 2002
U.S. Patent Application No. 10/466,136 filed 10 Jul 2003
Portfolios: Internal Medicine Cancer
Cancer -Therapeutics-Biological Response Modifiers-Other Cancer -Therapeutics Internal Medicine-Therapeutics
For Additional Information Please Contact: Susan S. Rucker J.D.
NIH Office of Technology Transfer
6011 Executive Blvd, Suite 325
Rockville, MD 20852-3804
Phone: (301) 435-4478
Email: ruckersu@mail.nih.gov
Fax: (301) 402-0220
